India Proposes New Import Points for Drugs and Medical Devices

The Union Health Ministry of India has put forward a proposal to broaden the list of authorised entry points for importing drugs, medical devices, and cosmetics. This move aims to streamline customs clearance and enhance the efficiency of the supply chain for these critical products.

The ministry’s recommended changes involve amending Rule 43A of the Drugs Rules, 1945. This rule currently defines which ports, airports, and railway stations are permitted to handle the import of regulated goods. The proposed revision would add several inland container depots (ICDs), a special economic zone (SEZ), and an international airport across multiple states, according to an official gazette notification.

Specifically, the new import gateways would include ICDs at Sonipat, Piyala, and Harsaru in Haryana; Dadri in Uttar Pradesh; Gandhidham and Mundra in Gujarat; Sanath Nagar and Thimmapur in Hyderabad, Telangana; and Whitefield in Bengaluru, Karnataka. Additionally, the Bommasandra SEZ in Karnataka and the Noida International Airport in Uttar Pradesh are planned to be recognised as authorised points for importing drugs by air.

This development is significant given the complex logistics involved in the pharmaceutical and medical device sectors. India is a major player in the global pharmaceutical industry, both as a producer and consumer. Efficient import channels help ensure that medicines, medical equipment, and related products reach the market promptly, supporting public health needs.

Inland container depots serve as important hubs for cargo handling away from traditional seaports, reducing congestion and enabling faster customs clearance. Including more ICDs allows importers and distributors to receive shipments closer to their locations, cutting down transit times and logistical costs.

The addition of a special economic zone as an authorised import point also reflects the growing role of SEZs in India's industrial and export infrastructure. SEZs often offer tax benefits, streamlined procedures, and infrastructure that encourage manufacturing and trade activities. By permitting drug imports directly through the Bommasandra SEZ, the government aims to facilitate smoother supply chains for pharmaceutical companies operating there.

Furthermore, recognising Noida International Airport for drug imports by air is a strategic step. As air freight is crucial for time-sensitive medical supplies, opening more airports for such imports can reduce delays caused by limited entry points and improve access to essential health products across northern India.

The proposed amendment underscores the government’s intent to modernise and expand the regulatory framework governing drug and medical device imports. By diversifying and increasing the number of authorised entry points, the ministry is addressing challenges related to supply chain bottlenecks and customs processing times.

India’s healthcare sector depends heavily on imports for certain specialised drugs, raw materials, and advanced medical devices. Efficient import infrastructure is vital to maintaining steady availability and affordability of these products for both domestic use and export.

Industry stakeholders are likely to welcome the expansion of import gateways, as it can reduce logistical hurdles and enhance competitiveness. The move also aligns with broader government efforts to boost manufacturing and trade efficiency within the pharmaceutical and healthcare segments.

The amendment to Rule 43A is currently in the proposal stage and will undergo necessary consultations before final implementation. Once enacted, the expanded network of authorised import points is expected to improve the overall ease of doing business in the drug and medical device sectors.

In summary, the Union Health Ministry’s plan to add multiple inland container depots, a special economic zone, and an airport for drug and medical device imports highlights a proactive approach to strengthening India’s healthcare supply chain infrastructure. This step is part of ongoing efforts to support faster clearance, reduce delays, and enhance the availability of critical health products across the country.